Progressive multifocal leukoencephalopathy and granule cell neuronopathy with novel mutation flanking VP1 C-terminus in natalizumab-extended interval dosing

Neurol Neuroimmunol Neuroinflamm. 2020 Mar 20;7(3):e709. doi: 10.1212/NXI.0000000000000709. Print 2020 May 4.

Authors

Torge Rempe¹, Qin Wang², Qi Wu², Varalakshmi Ballur Narayana Reddy², Zachary Newcomer², Augusto Miravalle², Yang Mao-Draayer¹

Affiliations

¹ From the Department of Neurology (T.R., V.B.N.R., Z.N., A.M.), University of Florida, Gainesville; and Department of Neurology (Q. Wang, Q. Wu, Y.M.-D.), University of Michigan, Ann Arbor. torge.rempe@neurology.ufl.edu maodraay@umich.edu.
² From the Department of Neurology (T.R., V.B.N.R., Z.N., A.M.), University of Florida, Gainesville; and Department of Neurology (Q. Wang, Q. Wu, Y.M.-D.), University of Michigan, Ann Arbor.

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Capsid Proteins / genetics*
Cerebellar Diseases / etiology*
Female
Humans
Immunologic Factors / adverse effects*
JC Virus / genetics*
Leukoencephalopathy, Progressive Multifocal / etiology*
Multiple Sclerosis, Relapsing-Remitting / drug therapy*
Natalizumab / adverse effects*

Substances

Capsid Proteins
Immunologic Factors
Natalizumab